CytoSorbents Europe GmbH
The objective of this study is to assess the safety and performance of the CytoSorb® therapy in patients with Acute on Chronic Liver Failure (ACLF) grade ≥ 2 due to a severe alcohol induced hepatitis (Maddrey DF > 32) and a severe inflammatory response.
Acute on Chronic Liver Failure
Alcoholic Hepatitis
CytoSorb® treatment
Study Type : | Observational |
Estimated Enrollment : | 0 participants |
Official Title : | A Prospective, Multi-Centre, Propensity Score Based Matched Pair Controlled, Study of Standard Medical Care Plus CytoSorb® 300 mL Device Compared to Standard Medical Care Alone in Patients With Acute on Chronic Liver Failure Due to Severe Alcoholic Hepatitis in Combination With Systemic Hyperinflammation and Acute on Chronic Liver Failure Score ≥2 |
Actual Study Start Date : | March 15, 2022 |
Estimated Primary Completion Date : | March 2023 |
Estimated Study Completion Date : | April 2023 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
University Hospital Knappschaftsklinikum Bochum GmbH
Bochum, Germany, 44892
Not yet recruiting
University of Rostock
Rostock, Germany, 18055